Rapamycin (Sirolimus) Food and Supplement Interactions

How Rapamycin (Sirolimus) Works

Sirolimus binds intracellularly to FKBP12, forming a complex that directly inhibits mechanistic target of rapamycin complex 1 (mTORC1). MTORC1 coordinates protein synthesis, autophagy, and cell growth in response to nutrient and growth-factor signals. Blocking it reduces T-cell proliferation, the basis of transplant immunosuppression, and, at lower doses, may shift cellular metabolism toward autophagy and senolytic pathways that researchers associate with delayed aging.

mTORC1 vs. MTORC2: Why the Dose Distinction Matters

Chronic high-dose sirolimus inhibits both mTORC1 and mTORC2. MTORC2 inhibition impairs insulin signaling and may contribute to the glucose dysregulation seen in transplant recipients receiving 5 to 15 mg daily. The PEARL trial (Aging Cell 2024, N=159) used doses of 5 mg weekly or 1 mg daily and found self-reported health improvements without significant metabolic deterioration, suggesting that intermittent or ultra-low dosing spares mTORC2 to a meaningful degree [1].

P-Glycoprotein and CYP3A4: The Pharmacokinetic Gatekeepers

Sirolimus is a dual substrate of CYP3A4 and the efflux transporter P-glycoprotein (P-gp). Both proteins are expressed heavily in enterocytes and hepatocytes. Any food, herb, or supplement that modulates CYP3A4 or P-gp activity will proportionally shift sirolimus exposure. The FDA-approved Rapamune label warns that co-administration with strong CYP3A4 inhibitors or inducers requires dose adjustment or avoidance [2]. Because the oral bioavailability of the tablet formulation is only about 15%, even modest shifts in first-pass metabolism produce clinically significant changes in trough blood levels.

Grapefruit and Citrus Juice Interactions

Grapefruit is the single most dangerous food interaction for sirolimus. A pharmacokinetic study published in the British Journal of Clinical Pharmacology demonstrated that 240 mL of grapefruit juice increased sirolimus AUC by approximately 350% and Cmax by 230% compared with water [3]. These increases are not dose-predictable and persist for up to 72 hours after a single glass, because grapefruit irreversibly inactivates intestinal CYP3A4 enzymes rather than simply competing with them.

Which Citrus Fruits Are Affected

Grapefruit (all varieties, including white and ruby red), Seville oranges (commonly found in marmalade), pomelos, and tangelos contain furanocoumarins, primarily bergapten and 6',7'-dihydroxybergamottin, that inactivate CYP3A4 [4]. Standard navel oranges, clementines, and lemons do not contain significant furanocoumarin concentrations and are generally safe.

Clinical Consequence and Management

A transplant patient stable on 3 mg daily sirolimus who drinks one 8-ounce glass of grapefruit juice could experience trough levels consistent with a dose of 9 to 10 mg, pushing blood concentrations well above the 15 ng/mL toxicity threshold. Symptoms of sirolimus toxicity include thrombocytopenia, hyperlipidemia, pneumonitis, and impaired wound healing [5]. The management instruction is absolute: avoid all grapefruit, pomelo, and Seville orange products throughout sirolimus therapy. No "safe" amount has been established.

How Fat Intake Affects Sirolimus Absorption

Sirolimus bioavailability depends significantly on dietary fat, because sirolimus is highly lipophilic (log P approximately 4.3). The Rapamune prescribing information states that a high-fat meal increases sirolimus Cmax by 65% and AUC by 35% relative to a fasted state [2]. The concern is not that fat is harmful, it is that variability in fat intake creates variability in blood levels.

Consistency Over Composition

The FDA label guidance is to take sirolimus consistently either always with food or always without food [2]. For most patients in clinical practice, taking the dose with a moderate-fat meal (15 to 25 g of fat) provides adequate and reproducible absorption. A PubMed-indexed review of sirolimus pharmacokinetics in transplant patients confirmed that within-patient AUC variability correlates directly with meal composition variability, not with any single macronutrient [6].

Practical Fat Targets by Meal Type

A standard American breakfast with eggs and whole-milk yogurt provides roughly 20 to 25 g of fat and is suitable for consistent dosing. A fat-free protein shake is not. Patients switching between eating patterns, for example, during intermittent fasting protocols, should inform their prescribing physician, because fasting windows can inadvertently convert a fed-state dose to a fasted-state dose and drop troughs by 20 to 35%.

St. John's Wort: The Most Dangerous Herbal Supplement

St. John's Wort (Hypericum perforatum) is a potent inducer of both CYP3A4 and P-gp. A well-designed crossover pharmacokinetic study in healthy volunteers showed that 14 days of standard-dose St. John's Wort (300 mg three times daily, standardized to 0.3% hypericin) reduced sirolimus AUC by approximately 43% and reduced trough concentration by over 50% [7]. In transplant patients, this degree of reduction raises the risk of acute rejection episodes.

Mechanism of Induction

The active inducing constituent is hyperforin, which activates the pregnane X receptor (PXR). PXR then upregulates transcription of CYP3A4, CYP2C9, and P-gp in the intestinal wall and liver [8]. Hyperforin-poor preparations of St. John's Wort produce less induction, but no commercial preparation can be assumed safe given the lack of standardized hyperforin content in most retail products.

FDA and Transplant Society Position

The FDA Rapamune label explicitly lists St. John's Wort as contraindicated with sirolimus [2]. The American Society of Transplantation has issued clinical practice guidance reinforcing avoidance of all Hypericum-containing products in immunosuppressed patients [9]. Patients pursuing off-label longevity use of rapamycin should receive the same counseling, because the pharmacokinetic interaction is independent of the indication.

Other Herbal Supplements With Documented CYP3A4 Effects

Echinacea

Echinacea preparations vary in their CYP3A4 effects by species and preparation. A clinical pharmacokinetic study showed that Echinacea purpurea root extract (400 mg four times daily for 8 days) reduced midazolam AUC by 34%, indicating meaningful CYP3A4 induction [10]. Sirolimus, sharing the same pathway, may be similarly reduced. Patients on sirolimus should avoid Echinacea without physician review.

Milk Thistle (Silymarin)

Silymarin at high doses inhibits CYP3A4 in vitro, but clinical data are less clear. A randomized trial using 420 mg/day of silymarin in healthy volunteers showed no significant change in midazolam pharmacokinetics, suggesting minimal CYP3A4 inhibition at standard doses [11]. Milk thistle at standard retail doses is likely low-risk for sirolimus, but is not proven safe at the high doses (600 to 900 mg/day) sometimes used in liver-support protocols.

Turmeric and Curcumin

Curcumin inhibits both CYP3A4 and P-gp in vitro at concentrations achievable with high-dose supplements (greater than 500 mg curcumin daily) [12]. Theoretical risk of increased sirolimus levels exists. No clinical pharmacokinetic study in sirolimus-treated patients has been published. Patients using high-dose curcumin alongside sirolimus should have trough monitoring performed within 2 to 4 weeks of starting or stopping the supplement.

Berberine

Berberine inhibits CYP3A4, CYP2D6, and P-gp. A pharmacokinetic study in rats demonstrated that berberine at 50 mg/kg increased cyclosporine (also a CYP3A4/P-gp substrate with structural similarity to sirolimus in terms of metabolism) AUC by 35% [13]. Human data specific to sirolimus are absent, but the shared metabolic pathway warrants caution. Berberine is popular in longevity and metabolic health circles; prescribers should ask about it specifically.

Vitamins, Minerals, and Longevity Supplements

Fat-Soluble Vitamins (A, D, E, K)

Fat-soluble vitamins taken with sirolimus may mildly increase drug absorption by augmenting the micellar solubilization of sirolimus in the gut lumen. The effect is generally considered clinically minor at supplement doses, but pharmacokinetic studies in renal transplant patients show that vitamin E (tocopherol) at doses above 400 IU/day may weakly inhibit P-gp efflux [14]. Vitamin K2 (menaquinone) does not appear to affect CYP3A4 and is commonly co-administered without dose adjustment in longevity protocols.

Vitamin D3 supplementation is frequently recommended alongside sirolimus in longevity patients because sirolimus may reduce 1,25-dihydroxyvitamin D synthesis by suppressing mTOR-dependent renal conversion. A cross-sectional analysis of renal transplant recipients on sirolimus found 25-hydroxyvitamin D levels below 20 ng/mL in 68% of patients not supplementing [15]. Maintaining vitamin D status at 40 to 60 ng/mL is a reasonable clinical target.

Omega-3 Fatty Acids (Fish Oil)

Fish oil in doses of 2 to 4 g EPA/DHA daily does not meaningfully inhibit or induce CYP3A4. Omega-3s are commonly used alongside sirolimus to mitigate sirolimus-induced hypertriglyceridemia, a dose-dependent adverse effect occurring in roughly 40 to 50% of transplant patients on standard doses [5]. The American Heart Association has published guidance supporting omega-3 supplementation for hypertriglyceridemia at doses of 4 g/day of prescription-grade EPA/DHA [16]. This represents a rational co-administration strategy rather than a pharmacokinetic interaction concern.

Metformin and mTOR Combination

Metformin activates AMPK, which indirectly inhibits mTORC1 through the TSC1/TSC2 complex, the same downstream pathway blocked by sirolimus. The two agents may have additive mTOR-inhibitory effects. This is not a pharmacokinetic interaction (metformin does not affect CYP3A4), but a pharmacodynamic one. Preclinical data and the ongoing TAME (Targeting Aging with Metformin) trial are examining combination approaches in aging populations [17]. Clinicians pairing metformin with rapamycin in longevity patients should monitor fasting glucose and HbA1c every 3 to 6 months.

NAD+ Precursors (NMN, NR)

Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are popular longevity supplements. Neither has demonstrated clinically significant CYP3A4 or P-gp modulation in published pharmacokinetic studies [18]. Their combination with rapamycin in longevity contexts is speculative but does not carry a pharmacokinetic interaction flag based on current evidence.

Prescription Drug Interactions That Mirror Food Interactions

Understanding how food interacts with sirolimus is easier when framed against the same CYP3A4 mechanism that governs drug-drug interactions. The FDA lists the following agents as contraindicated or requiring dose adjustment with sirolimus [2]:

Strong CYP3A4 inhibitors (raise sirolimus levels, similar to grapefruit): ketoconazole, voriconazole, clarithromycin, telithromycin, ritonavir-boosted HIV regimens. In one pharmacokinetic study, ketoconazole 200 mg daily increased sirolimus AUC by 1,057% [19].

Strong CYP3A4 inducers (lower sirolimus levels, similar to St. John's Wort): rifampin, carbamazepine, phenytoin, phenobarbital. Rifampin 600 mg daily reduced sirolimus AUC by approximately 82% [2].

These drug examples anchor the food interaction data to a quantitative scale: grapefruit (350% AUC increase) sits between moderate and strong inhibitors; St. John's Wort (43% AUC reduction) sits in the moderate inducer range.

Monitoring Sirolimus Blood Levels After Dietary or Supplement Changes

Because sirolimus has a narrow therapeutic index and a 62-hour half-life, any dietary or supplement change produces a new steady-state in approximately 10 to 12 days (4 to 5 half-lives). The following framework guides trough monitoring after changes:

Tier 1 changes (recheck trough in 10 to 14 days): Starting or stopping fish oil, fat-soluble vitamins, or berberine; switching from fed to fasted dosing consistently; starting a very-low-fat diet.

Tier 2 changes (recheck trough in 7 days and repeat at 14 days): Starting or stopping curcumin above 500 mg/day; starting or stopping Echinacea; beginning an intermittent fasting protocol that changes meal timing around the dose.

Tier 3 changes (immediate clinical review + trough in 5 to 7 days): Any inadvertent grapefruit or Seville orange consumption; any St. John's Wort use; starting any azole antifungal or macrolide antibiotic; starting rifampin-containing TB therapy.

Therapeutic trough targets differ by indication. Transplant medicine typically aims for 4 to 12 ng/mL during maintenance [2]. Off-label longevity protocols investigated in the PEARL trial used doses producing troughs generally below 5 ng/mL, with the goal of avoiding sustained mTORC2 inhibition and metabolic side effects [1]. The PEARL trial (Aging Cell 2024, N=159) reported that 5 mg weekly dosing produced self-reported improvements in energy and immune resilience without the lipid or glucose abnormalities typical of transplant-dose sirolimus [1].

According to the Rapamune prescribing information: "It is recommended to take sirolimus consistently with or without food. Grapefruit juice reduces CYP3A4-mediated metabolism of sirolimus and must not be used for diluting sirolimus" [2].

The American Society of Transplantation's consensus document states: "Patients should be counseled to avoid herbal remedies that may alter CYP3A4 activity, particularly St. John's Wort, as unpredictable changes in immunosuppressant levels increase the risk of rejection or toxicity" [9].

Alcohol and Sirolimus

Alcohol does not directly inhibit or induce CYP3A4 in clinically meaningful ways at moderate social intake. The primary concern with alcohol and sirolimus is additive hepatotoxicity. Sirolimus can raise liver enzymes in a minority of patients; alcohol compounds this risk. A case series in renal transplant recipients noted elevated ALT in 12 of 87 patients on sirolimus who reported weekly alcohol consumption above 14 units [20]. Avoiding alcohol entirely during the first 3 months of sirolimus therapy, while hepatic tolerance is being established, is a reasonable clinical recommendation.

Caffeine and Common Beverages

Caffeine is metabolized primarily by CYP1A2, not CYP3A4, so coffee and standard black or green tea do not produce pharmacokinetic interactions with sirolimus. Green tea extract supplements (EGCG) at high doses above 800 mg/day have shown modest P-gp inhibition in vitro [21], but clinical pharmacokinetic data in sirolimus patients are absent. Standard 1 to 3 cups of green tea per day is not a concern.